As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cullinan Therapeutics, Inc. The largest reported stake is Bvf Partners L P's, at 9.99%. 15 filings are on record since August 6, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Cullinan Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 3,711,284 · Sole dispositive: 0 · Shared dispositive: 3,711,284 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 3,825,950 · Shared voting: 0 · Sole dispositive: 3,825,950 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 3,565,748 · Sole dispositive: 0 · Shared dispositive: 3,668,627 · SCHEDULE 13G, 2026-08-07
- · Holder: Bvf Partners L P · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Cullinan Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-08-06. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bvf Partners L P | 9.99% | 6,491,123 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Lynx1 Capital Management LP | 9.8% | 5,766,090 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| T. Rowe Price Associates, Inc. | 6.2% | 3,825,950 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 6% | 3,668,627 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Kynam Capital Management, LP | 5.27% | 3,114,132 | SCHEDULE 13G, 2026-03-04 | 2025-12-31 |
| Deerfield Mgmt, L.P. | 4.95% | 2,927,013 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| 3.4% | 1,988,907 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Cullinan Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cullinan Therapeutics, Inc. and the records around it.
Cullinan Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
Watch Cullinan Therapeutics, Inc.
Get an email when Cullinan Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cullinan Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cullinan Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cullinan Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 0 | 3,711,284 | 0 | 3,711,284 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf I Gp LLC | 0 | 3,711,284 | 0 | 3,711,284 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund Ii LP | 0 | 2,269,166 | 0 | 2,269,166 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Ii Gp LLC | 0 | 2,269,166 | 0 | 2,269,166 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Trading Fund OS LP | 0 | 400,861 | 0 | 400,861 | SCHEDULE 13G/A, 2026-08-14 |
| BVF Partners OS Ltd. | 0 | 400,861 | 0 | 400,861 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Gp Holdings LLC | 0 | 5,980,450 | 0 | 5,980,450 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Partners L P | 0 | 6,491,123 | 0 | 6,491,123 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Inc | 0 | 6,491,123 | 0 | 6,491,123 | SCHEDULE 13G/A, 2026-08-14 |
| Lampert Mark N | 0 | 6,491,123 | 0 | 6,491,123 | SCHEDULE 13G/A, 2026-08-14 |
| T. Rowe Price Associates, Inc. | 3,825,950 | 0 | 3,825,950 | 0 | SCHEDULE 13G, 2026-08-14 |
| State Street Corporation | 0 | 3,565,748 | 0 | 3,668,627 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Cullinan Therapeutics, Inc. by CUSIP 230031106 and gives its principal executive office as ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA 02142 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Kenneth Griffin | 5.1% | SCHEDULE 13G |
| 2025-08-14 | Lynx1 Capital Management LP | 7.5% | SCHEDULE 13G |
| 2025-10-10 | Lynx1 Capital Management LP | 14.5% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 4.98% | SCHEDULE 13G/A |
| 2025-11-13 | Deerfield Mgmt, L.P. | 4.95% | SCHEDULE 13G/A |
| 2025-11-14 | Lynx1 Capital Management LP | 9.8% | SCHEDULE 13G/A |
| 2025-11-14 | Kenneth Griffin | 3.4% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 5.58% | SCHEDULE 13G |
| 2026-02-17 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-03-04 | Kynam Capital Management, LP | 5.27% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 6% | SCHEDULE 13G |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 6.2% | SCHEDULE 13G |
| 2026-08-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
Questions about who owns Cullinan Therapeutics, Inc.
Who owns Cullinan Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Cullinan Therapeutics, Inc.: Bvf Partners L P (9.99%, Schedule 13G/A, filed 2026-08-14), Lynx1 Capital Management LP (9.8%, Schedule 13G/A, filed 2025-11-14), T. Rowe Price Associates, Inc. (6.2%, Schedule 13G, filed 2026-08-14), State Street Corporation (6%, Schedule 13G, filed 2026-08-07) and Kynam Capital Management, LP (5.27%, Schedule 13G, filed 2026-03-04).
Who are the largest shareholders of Cullinan Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Cullinan Therapeutics, Inc. on this page are Bvf Partners L P (9.99%), Lynx1 Capital Management LP (9.8%) and T. Rowe Price Associates, Inc. (6.2%).
When did Bvf Partners L P buy into Cullinan Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Cullinan Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.